PACAP deficiency as a model of aging

D. Reglodi, T. Atlasz, E. Szabo, A. Jungling, A. Tamas, T. Juhasz, B. D. Fulop, A. Bardosi

Research output: Review article

19 Citations (Scopus)


Dysregulation of neuropeptides may play an important role in aging-induced impairments. In the long list of neuropeptides, pituitary adenylate cyclase–activating polypeptide (PACAP) represents a highly effective cytoprotective peptide that provides an endogenous control against a variety of tissue-damaging stimuli. PACAP has neuro- and general cytoprotective effects due to anti-apoptotic, anti-inflammatory, and antioxidant actions. As PACAP is also a part of the endogenous protective machinery, it can be hypothesized that the decreased protective effects in lack of endogenous PACAP would accelerate age-related degeneration and PACAP knockout mice would display age-related degenerative signs earlier. Recent results support this hypothesis showing that PACAP deficiency mimics aspects of age-related pathophysiological changes including increased neuronal vulnerability and systemic degeneration accompanied by increased apoptosis, oxidative stress, and inflammation. Decrease in PACAP expression has been shown in different species from invertebrates to humans. PACAP-deficient mice display numerous pathological alterations mimicking early aging, such as retinal changes, corneal keratinization and blurring, and systemic amyloidosis. In the present review, we summarize these findings and propose that PACAP deficiency could be a good model of premature aging.

Original languageEnglish
Pages (from-to)437-452
Number of pages16
Issue number5-6
Publication statusPublished - dec. 1 2018


ASJC Scopus subject areas

  • Ageing
  • Geriatrics and Gerontology

Cite this

Reglodi, D., Atlasz, T., Szabo, E., Jungling, A., Tamas, A., Juhasz, T., Fulop, B. D., & Bardosi, A. (2018). PACAP deficiency as a model of aging. GeroScience, 40(5-6), 437-452.